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What is already known about the subject? 
 Cirrhosis is on the rise with little proven treatment that affects its natural history or 
mortality 
 The risk of hip fracture is increased among some groups of people with cirrhosis 
 Hip fracture confers a large morbidity and mortality effect immediately following the 
event 
 There is lack of evidence on the absolute and relative hip fracture risk specifically in 
patients with alcoholic cirrhosis, taking into account competing risk of death. 
 
What are the new findings? 
 Hip fracture risk is raised by at least 5 fold in an alcoholic cirrhosis population 
compared to population controls of similar age and sex 
 The increased risks of hip fracture is higher in younger adults 
 The cumulative incidence of hip fracture (having taken account of the competing risk 
of death) is greater than that of hepatocellular carcinoma (HCC) in this population. 
 
How might it impact on clinical practice in the foreseeable future? 
 Hip fracture is, via several interventions, potentially preventable. Given that the 
reported risk of hip fracture in people with cirrhosis is higher than that of HCC for 
which there is national surveillance, our findings support the need for more effort 
towards fracture prevention in this population as it could benefit both the individual 
and society burden. 
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Abstract 
Background & aims: Cirrhosis is a risk factor for osteoporosis and fractures. However, little 
is known of the actual risk of hip fractures in patients with alcoholic cirrhosis.  Using linked 
primary and secondary care data from the English and Danish nationwide registries, we 
quantified the hip fracture risk in two national cohorts of patients with alcoholic cirrhosis. 
 
Methods: We followed 3,706 English  and 17,779 Danish patients with a diagnosis of 
alcoholic cirrhosis, and we identified matched controls from the general populations. We 
estimated hazard ratios (HR) of hip fracture for patients versus controls, adjusted for age, 
sex and comorbidity.  
 
Results: The 5-year hip fracture risk was raised both in England (2.9% vs 0.8% for controls) 
and Denmark (4.6% vs 0.9% for controls). With confounder adjustment, patients with 
cirrhosis had 5-fold (adjusted HR 5.5 (95% CI 4.3-6.9)), and 10-fold (adjusted HR 9.9 (95% 
CI 8.9-11.0)) increased rates. This association between alcoholic cirrhosis and risk of hip 
fracture showed significant interaction with age (p<0.001), being stronger in younger age 
groups (under 45 years HR: 17.9 and 16.6 respectively for English, Danish) than in patients 
over 75 years (HR 2.1 and 2.9 respectively). In patients with alcoholic cirrhosis, 30-day 
mortality following a hip fracture was 11.1% in England  and 10.0% in Denmark, giving age-
adjusted post-fracture mortality rate ratios of 2.8(95% CI 1.9-3.9) and 2.0(95% CI 1.5-2.7), 
respectively. 
 
Conclusions: Patients with alcoholic cirrhosis have a markedly increased risk of hip fracture 
and post-hip fracture mortality compared with the general population.  
 
Keywords: cirrhosis; epidemiology; fracture 
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Introduction  
An important and often studied complication of chronic liver disease is osteoporosis (1–5). 
Osteoporosis may be asymptomatic, but increases the risk that minor accidents result in 
bone fractures, particularly of the distal radius and proximal femur (1,2). Hip fractures in 
particular have a significant impact on health, productivity and life expectancy (6,7), and the 
30-day mortality is estimated to be up to 10% (8,9). In patients specifically with alcoholic 
cirrhosis, the risk of these fractures may be further increased due to the direct effect of high 
levels of alcohol use (10), or minimal hepatic encephalopathy (11). However, due to a dearth 
of studies that have actually quantified the incidence of fractures in chronic liver disease, the 
absolute risk of hip fractures in people with alcoholic cirrhosis is unknown.  
Available estimates on the occurence of fractures in hepatic disorders originate from small 
studies on hetergenous populations that were carried out almost 10 years ago. Only two 
recent studies have addressed the risk of fractures in alcoholic liver disease specifically 
(5,12), but – like previous studies (13,14) – they studied relative risks, not absolute risks and 
did not do a comprehensive analysis by fracture type, so estimates of hip fracture specifically 
are unavailable. Clinical practitioners and policy makers would be better placed to inform 
and guide patients regarding prevention strategies if their actual risk of serious injury, such 
as hip fracture, was known. Indeed, while the relative risk of a hip fracture is useful in terms 
of identifying a group in which targeted intervention could be valuable, without absolute risks 
it is impossible to judge the risks and benefits of potential interventions. In a cirrhosis 
population it is crucial also when quantifying risk to take account of the fact that there is a 
high mortality (15,16). Only by accounting for this competing risk and demonstrating the 
cumulative risk of hip fracture can we accurately quantify the problem. We therefore have 
performed a large study using two national cohorts in England and Denmark to examine the 
absolute and relative risk of incident hip fracture in patients with alcoholic cirrhosis compared 
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with the general population, and to compare and contrast our findings given the differences 
in the populations of the two countries. 
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Methods  
Data sources 
English data was obtained from the linked Clinical Practice Research Datalink (CPRD) and 
Hospital Episodes Statistics (HES) database (17,18), while Danish data was obtained from 
The Danish National Patient Registry (NPR) (19) and the Danish civil registration system 
(20). 
 
Clinical Practice Research Datalink (CPRD) and Hospital Episodes Statistics (HES) 
The CPRD consists of computerised general practice records for over 15 million patients in 
the UK of which 4.4 million are active, alive and currently registered. With a coverage of 4.4 
million, it covers approximately 6% of the UK population. Recorded data includes patient 
demography, diagnoses and test results entered during general practice appointments or 
following communication from secondary care.  These data are coded electronically using 
the hierarchical Read coding system (21) and are subjected to regular data quality checks 
and audits to ensure 95% inclusion of prescribing and morbidity events. Since 1997, the 
CPRD has an established linkage to the HES database, which contains information on all 
admissions to the state-funded National Health Service (NHS) hospitals in England; 
including secondary care diagnoses coded using the International Classification of Disease 
(ICD) edition 10 (ICD-10).  Approval for use of this linked data for this study was given by the 
Scientific and Ethical Committee of the CPRD (15_073RAR). 
 
National Patient Registry (NPR) 
The Danish NPR is a nationwide registry that holds data on all admissions to non-psychiatric 
hospitals since 1977 and from outpatient and emergency room visits since 1995 in Denmark. 
The data includes dates and diagnoses coded in accordance with the ICD-10 from 1994 and 
ICD-8 before that. The Danish Central Office of Civil Registration (CPR) monitors the vital 
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status of all Danish citizens (population 5.6 million) continuously and issues a unique 
personal identifier to everyone at birth or migration to Denmark. This number enables 
individual-level linkage with the NPR. 
 
Study population 
All adults (>18 years) with a first time diagnosis of alcoholic cirrhosis between 1997 and 
2014 were identified. Alcoholic cirrhosis was defined by the presence of a diagnostic code 
(Read or ICD-10 code) for alcoholic cirrhosis. Our code lists were adapted from previously 
validated definitions (22,23). We defined the ’index date’ of each patient as the first date of a 
recorded diagnostic code for alcoholic cirrhosis. Among the patients identified within the 
English data, we excluded those with an index date within 1 year of registration with a 
general practice in order to avoid prevalent cases. For each included patient, we identified 
up to 10 general population controls frequency-matched on sex, age (within 5 years) and by 
registration at the same general practice, (general practice matching was for patients 
identified in England only). The matched controls had to be alive and without a diagnostic or 
therapeutic code for cirrhosis, oesophageal varices and/or portal hypertension within their 
own general practice or hospital record.  
Controls identified for the English cohort were assigned an index date, which was a 
randomly generated date from 1 year after the start of the linked dataset (1997) up to the 
date they left their general practice or died. For the Danish cohort, controls were assigned 
the same index date as the cirrhosis patient they were matched to. Patients with a diagnosis 
of a hip fracture (as defined below) before the index date were excluded from both cohorts. 
 
Study period 
Each patient and control was followed from the index date to a diagnosis for a hip fracture, 
date of death, date of moving out of their general practice (for English data only), or end of 
follow-up (31/12/2014). 
 
8 
 
Study definitions 
Primary outcome 
The primary outcome was time to first diagnosis for any hip fracture (ICD-10 S720-S729; 
Read codes 820 A, 820 B, 8210, S30..00, S30..11, S302.00, S30y.00, S30y.11, S30z.00) as 
recorded on the general practice, hospital, or patient registry records (24). 
 
Severity of cirrhosis 
Patients with alcoholic cirrhosis were classified as being in a compensated or 
decompensated disease state according to the Baveno clinical staging classification that 
takes into account the absence or presence of variceal bleed, and ascites (but specifically 
does not include hepatic encephalopathy) (25) . Variceal bleed or ascites was defined if 
there was a relevant diagnostic code (ICD-10 code:  R18, I850, K920, K921, K922, I859, 
I864, I982) or procedure code (OPCS4 code: T461, T462, G104, G108, G109, G144, G174, 
G437) up to 1 year before the date of diagnosis of alcoholic cirrhosis; cirrhosis patients 
without such codes were defined as having compensated disease.  We specifically identified 
evidence of hepatic encephalopathy by searching patient records for relevant diagnostic 
codes (ICD 10: E51.2, G31.2, K70.4, K72.1). 
 
Other cirrhosis aetiologies 
We reported whether our patients with alcoholic cirrhosis also had cirrhosis of other etiology 
including viral hepatitis, autoimmune liver disease (primary biliary cholangitis, primary 
sclerosing cholangitis and autoimmune hepatitis), haemochromatosis, Wilson’s disease and 
alpha-1 antitrypsin deficiency at any time prior to alcoholic cirrhosis diagnosis using methods 
described previously(22).  
 
Comorbidity 
For each cirrhosis patient and population control, we used secondary care data recorded 
within two years before the index date to compute their Charlson Comorbidity Index (CCI) 
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(26). The CCI is a weighted comorbidity score that is defined for use in the ICD-10. It 
includes myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, mild liver disease, dementia, chronic pulmonary disease, 
rheumatic disease, peptic ulcer, diabetes with or without complications, hemiplegia or 
paraplegia, renal disease, moderate or severe liver disease, cancer, metastatic cancer, and 
HIV/AIDS. Diagnoses related to liver disease were excluded when calculating the CCI for 
this study. For clarity of presentation, we summarized the CCI in three categories: no 
comorbidity (CCI = 0), moderate comorbidity (CCI = 1), and multiple or severe comorbidity 
(CCI≥ 2).  
 
 
Potential confounders 
We extracted data on patients with an osteoporosis diagnosis. In addition, where available, 
we extracted data on drug exposure to oral and injected steroids, antidepressants, opiates 
and bisphosphonates. These drugs were chosen because they have been previously shown 
to be associated with fracture or are used as a treatment for osteoporosis(27).  A density 
parameter for each subject was defined as the number of prescriptions received (with a 
maximum of 1 prescription per day per drug category permitted) per follow-up time as 
defined below.  This prescription density was then categorised, for each drug category, into 
none, some and many of the specific prescriptions.  The categorisation of some and many 
was made, for each drug, as ‘less than or equal to’ or ‘greater than’ the median density of 
prescriptions (having excluded those with zero prescriptions). 
 
Statistical analyses 
We calculated the rate of first hip fracture in alcoholic cirrhosis patients and population 
controls. Using Cox regression, we estimated the hazard ratio (HR) for a hip fracture in the 
alcoholic cirrhosis cohort compared with the control population.  All standard Cox regression 
models were a priori adjusted for age, sex and comorbidity at baseline (Charlson comorbidity 
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index, 0,1 or 2). We computed HRs for subgroups defined by age group, sex and cirrhosis 
severity (compensated or decompensated cirrhosis) and examined effect modification by 
age with the likehood ratio test and graphically using a Schoenfeld residuals plot. We 
computed the 1- and 5- year cumulative risk of a hip fracture after alcoholic cirrhosis 
diagnosis using the cumulative incidence function with death without hip fracture as the 
competing risk (using age as the timescale). Proportional hazards assumptions were 
confirmed using Schoenfeld residuals and log-log plots. Finally, we identified all deaths 
occuring within 30 days after hip fracture diagnosis and estimated 30-day mortality and 
mortality risk for cirrhosis patients versus the control population.  
 
Additional analyses 
We repeated our analyses on disease severity to include patients who had a clinical 
diagnosis of hepatic encephalopathy in the decompensated group. This enabled us to 
examine the effect of hepatic encephalopathy on the association between disease severity 
and fracture rates. We also stratified fracture estimates by the presence or absence of 
osteoporosis and bisphosphonate use, as these are on the causal pathway between 
cirrhosis and fractures and adjusting for them in our models would have been inappropriate. 
We assessed the effect of drug exposure using English data where prescription records are 
available. Drug exposure (oral and injected steroids, antidepressants, opiates) was modelled 
as a categorical variable and included in the a priori adusted cox regression model if it 
conferred a 10% adjustment in the hazard ratios seen (Supplementary tables 1 and 2). 
Finally, to examine the role of comorbidity on fracture rates, we re-estimated the 5-year 
cumulative incidence of fracture in only those patients with a Charlson comorbidity score of 0 
(Supplementary figure 1) i.e. no recorded comorbidity.  
All statistical analyses were conducted using Stata version 13.0 (StataCorp, College Station, 
TX). 
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Results 
Demographic and clinical characteristics 
In the English data, we included 3,706 alcoholic cirrhosis patients and 36,859 matched 
population controls. The median age at diagnosis was 56 years, 68.0% of patients were 
men, and 49.8% had decompensated cirrhosis at their diagnosis. At inclusion, cirrhosis 
patients had more comorbidity than population controls and the prevalence of a CCI score of 
1 or more was 37.7% in cirrhosis patients and 7.1% in population controls (Table 1).  
In the Danish data, we included 17,779 cirrhosis patients and 80,815 population controls. 
They were slightly older than the English cirrhosis patients (median age 57 years), but their 
gender composition was similar to English cirrhosis patients (66.8% were men). The 
prevalence of decompensated cirrhosis at the diagnosis for cirrhosis was 30% and Danish 
cirrhosis patients also had more comorbidity than population controls; the prevalence of a 
CCI score of 1 or more was 36.6% in cirrhosis patients and 5.4% in population controls 
(Table 1).  In both England and Denmark, the majority of patients [English (88.8%) and 
Danish (94.6%)] had an alcohol-only cirrhosis aetiology (taking into account medical records 
before alcoholic cirrhosis diagnosis). Evidence of osteoporosis was found in 6.3% and 3.1% 
of English and Danish patients respectively. 
 
Fracture analysis 
We followed up the English population for a total of 177,717 person years, during which 485 
hip fractures occurred (108 fractures in cirrhosis patients, 377 fractures in controls). The 
absolute hip fracture rate for patients with cirrhosis was 11.4 fractures (95% CI: 9.4-13.8) per 
1000 person years but the rate among controls was much lower at 2.2 (95% CI: 2.0-2.5) per 
1000 person years (Table 2). In effect, there was an excess of 9.2 fractures per 1000 person 
years in English cirrhosis patients. The adjusted hip fracture hazard ratio for cirrhosis 
patients vs. controls was 5.5 (95% CI: 4.3-6.9) (Table 2). 
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The corresponding numbers for the Danish population were 753,797 person years of follow-
up and 2,491 fractures (977 fractures in cirrhosis patients and 1,514 fractures in controls). 
Similarly, the absolute hip fracture rate for Danish cirrhosis patients was higher than that of 
controls, at 16.0 (95% CI: 15.0-17.0) per 1000 person years compared to 2.2 (95% CI 2.1-
2.3) per 1000 person years (Table 2). Thus, there was an excess of 13.8 fractures per 1000 
person years in Danish cirrhosis patients over controls.  The adjusted hip fracture hazard 
ratio for Danish cirrhosis patients vs. controls was 8.5 (95% CI:  7.8–9.3).  
 
Fracture rate analysis by subgroups 
In both countries the association between cirrhosis and hip fracture rate was stronger in 
younger age groups (aged < 45 years) than in older age (p value for interaction with age 
<0.001). The hazard ratio of a hip fracture in those aged 45-54 years was 14.7 (95% CI 8.6-
24.9) and 13.1 (95% CI 10.9-15.7) in England and Denmark respectively, whereas for those 
aged 75 years and over it was 2.1 (95% CI 1.1-3.9) (England) and 3.0 (95% CI 2.1–4.2) 
(Denmark) (Table 2 and Figure 1). In Denmark, the association between cirrhosis and hip 
fracture rate was slightly stronger in men (HR 9.0, 95% CI 8.0–10.1) than in women (HR 7.9 
,95% CI 6.9–9.0) but in England it was stronger in women (HR 7.1 (95% 5.0- 9.9)) than in 
men (HR 4.4 (95% 3.2 – 6.1)).  Disease severity had no remarkable effect on absolute 
fracture rate in Demark, but in England, absolute fracture rates were higher in patients with 
decompensated disease than in compensated disease (14.2 vs. 9.4 per 1,000 person 
years). Including hepatic encephalopathy in the definition of disease severity had a minimal 
effect on the association between disease severity and fracture rates. 
 
1-year and 5-year cumulative incidence analysis 
After 1-year of follow-up, the cumulative hip fracture risk in English cirrhosis patients was 
1.0% (95% CI: 0.7–1.4) compared to 0.2% (95% CI: 0.1–0.3) for population controls. The 
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corresponding 5-year risks were also higher for cirrhosis patients than for controls at 2.9% 
(95% CI 2.3-3.6) vs. 0.8% (95% CI 0.7-0.9). Likewise, in the Danish cohort, the 1-year hip 
fracture risk for cirrhosis patients was higher than that of controls at 1.4% (95% CI: 1.2–1.6) 
vs 0.2% (95% CI: 0.1–0.2). The corresponding 5-year risks were 4.6% (95% CI: 4.3–5.0) 
and 0.9% (95% CI: 0.8–0.9) respectively. 
In both countries, the 5-year risks of hip fracture increased with increasing age and was 
higher for each cirrhosis age group than for the matched controls (Figure 2, Table 3). The 
cumulative risk among the young controls (less than 45 years) was very low, but the risk in 
young cirrhosis patients was remarkably high hence the increase in risk relative to the 
control population was greater in younger cirrhosis patients than in those over 75 years 
(Figure 2).  We found no variation in hip fracture risk by disease severity (Table 3). 
 
30-day mortality estimate 
By 30 days post hip fracture, 11.1% (12/108) of English cirrhosis patients and 10.0% 
(98/977) of Danish cirrhosis patients had died compared to 5.0% (England) and 6.6% 
(Denmark) for the control populations (Table 4). The adjusted mortality risk ratio comparing 
deaths in cirrhosis patients to controls was 2.8 (95% CI: 1.9-3.9) and 2.0 (95% CI: 1.5–2.7), 
for England and Denmark respectively. 
 
 
Additional analyses on drug use 
Supplementary Table 1 provides information on drug usage for the English cirrhosis and 
control cohort.  Patients with cirrhosis were more likely than controls to have had a 
prescription of opiates (42.2% vs 32.7%) and antidepresessants (14.2% vs 11.1%), but as 
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likely to have had a prescription for oral or injected corticosteroids( 13.9% vs. 14.7%) . As 
shown in supplementary table 2, there was only minimal confounding identified following 
adjustment for prescription drug use. 
 
Discussion 
Using data from two national cohorts, we have shown an increased rate of hip fracture for 
people with alcoholic cirrhosis of between 5-fold to nearly 10-fold compared with the general 
population. The 5-year risk of hip fracture was 2.9% for cirrhosis patients in the England and 
4.6% for patients in Denmark. In both countries, younger patients had the largest risk 
difference when comparing cirrhosis patients with controls. This association was due to the 
combination of a very low risk of hip fractures among young control patients and the 
contrasting high risk in young patients with alcoholic cirrhosis. We found a higher 30-day 
post-fracture mortality in cirrhosis patients of between 2 to 3 fold compared to population 
controls. Our study therefore indicates that interventions to prevent hip fracture in this 
population could have a significant benefit.   
 
We chose to combine two national cohorts for this analysis so that we could compare and 
contrast our findings, and explore some of the differences. There were many similarities 
between the alcoholic cirrhosis cohorts in both countries.  The age and sex profiles were 
very similar and the relative risks of fracture again were reasonably similar. Importantly the 
interaction with age showed the same pattern of relative and cumulative risks in both 
countries indicating its likely veracity.  Our conclusions were the same irrespective of the 
severity of alcoholic cirrhosis suggesting that the 20% difference in the prevalence of 
decompensation between both cohorts was not crucial to the interpretation of our analysis.  
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Strengths and limitations 
This is the first study to report the incidence of hip fracture in patients with alcoholic cirrhosis 
using prospectively collected data from two large national cohorts, with access to a suitable 
control population. Other strengths are its large size, competing risk adjustment, and 
population-based setting which means we have been able to estimate both the absolute and 
relative risks of hip fractures with reasonable precision and accuracy, and that these 
estimates are generalizable to the general populations of the two nations and possibly given 
the similarity between the results, to others as well. In addition, we were able to stratify 
estimates by age and sex, and by so doing have assessed for variation by these variables. 
Information on some other potential confounding factors (28,29) were either missing for 
some patients or absent in totality, e.g. weight bearing exercise, meaning that we could not 
assess their potential effect on our estimates. Our estimates were also not adjusted for 
alcohol use because heavy alcohol intake is an inherent part of having alcoholic cirrhosis 
and it would therefore be inappropriate to adjust for. Obviously, this means we do not know 
how much alcoholic individuals drank post-cirrhosis diagnosis nor how this might alter to 
their fracture risk.  However, the presence of an increased risk of fracture in non-alcoholic 
groups with liver injury(4) argues that alcohol cannot entirely account for the relationship 
shown in our study.   
The data sources used for this study have previously been validated and quality assured 
both for the diagnosis of cirrhosis (23,30) and for hip fracture (31,32). A validation of the 
severity of disease, as measured through decompensation, has not however been possible 
and as such, we may have missclassified some patients between stages of disease. 
Nevertheless, our previous work(33) has shown that the Baveno method of classifying 
decompensation accurately predicts mortality and as such appears a reasonably sound 
approach. Finally, while these results have important implications for fracture prevention in 
people with cirrhosis, this analysis does not consider the mechanism of fractures, thus it is 
not possible to explicitly attribute the increased risk of fractures to, for example, 
osteoporosis, trauma, both or some other risk factors.  Although we found 6.3% (England) 
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and 3.1% (Denmark) of patients with evidence of osteoporosis, these should be interpreted 
with caution as recording of osteoporosis diagnosis within our data is presumed to be 
incomplete and therefore underestimated. Future studies may consider exploring the 
prevalence of osteoporosis in alcoholic cirrhosis in more detail, given this lack of robust 
osteoporosis data in our study. 
 
Comparison with previous literature 
Previous publications on the association between osteoporosis, fractures and alcholic liver 
disease have been with small heterogenous populations and thus far, only relative risks 
have been presented. In 2014, Bang et al reported a relative fracture risk in people with 
alcoholic cirrhosis of 2.4, but this was based on a small subgroup of patients identified within 
a larger cohort of patients with either chronic pancreatitis or cirrhosis (5). In another meta-
analysis from the same group in 2015, based on six studies (34–39), a lower relative 
increase in fracture risk of 1.9 was found among people with alcoholic liver disease of mixed 
severity (12). Several other data for comparison originate from studies based on other 
chronic liver diseases. Tsai et al, estimated the risk of fractures in 3,764 patients with 
cirrhosis (most likely to be predominantly hepatitis-B related) compared to non-cirrhotic 
controls, and found a 4-fold increase in skull fracture risk in cirrhosis patients with hepatic 
encephalopathy (HE), and a 1.6- to 1.8-fold increase in spine, trunk and upper limb fracture 
risk in cirrhosis patients without HE (40). In two other studies using the same UK primary 
care database as our study, high relative increases in hip and wrist fracture rates of between 
1.9 and 4.0 were found in patients with primary biliary cholangitis (PBC) or any chronic liver 
disease (4,14).  
In our analysis accounting for death as a competing risk, we found no difference in the 
cumulative risk of fractures between patients with compensated and decompensated 
disease. These findings are consistent with two smaller studies on other advanced liver 
disease (PBC) which found no association between the occurrence of fractures and severity 
of liver disease (4,41).  
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Clinical implications and conclusion 
Overall, our study has shown that hip fracture is an important clinical outcome in patients 
with alcoholic cirrhosis due to its frequent occurrence and severe consequence. The 
cumulative risk of fracture, having accounted for the competing risk of death, in these 
patients is approximately 1% per annum and there is more than two fold higher post fracture 
30-day mortality in people with cirrhosis than in the general population. Currently, great 
emphasis is placed on Hepatocellular carcinoma (HCC) as an important, potentially 
preventable, cause of mortality in cirrhosis with several guidelines proposing national HCC 
surveillance to enhance detection and thus early treatment (42,43). Given that our study has 
shown that the cumulative incidence of hip fractures in alcoholic cirrhosis is higher than that 
of HCC (15,44), hip fractures may be an even more important cause of death and morbidity 
among people with alcoholic cirrhosis. To these facts can be added the knowledge that 
effective pharmacotherapy exists to treat osteoporosis and is proven to reduce hip fracture 
risk(45–48).     
Therefore, prophylaxis to reduce hip fracture occurrence in people with alcoholic cirrhosis 
(48–51),  may have greater potential for benefit than does the currently common practice of 
surveillance for HCC, and certainly warrants consideration alongside it.  
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Table 1. Demographic characteristics of alcoholic cirrhosis cohort and population 
controls in Denmark and England. 
                  UK                         Denmark 
 Cirrhosis 
patients 
N=3,706 
Controls 
N=36,854 
Cirrhosis 
patients 
N=17,779 
Controls 
N=80,815 
Age at diagnosis (%)     
≤44 645 (17.4) 7,426 (20.1) 2,117 (11.9) 10,033 (12.4) 
 45–54 1,089(29.4) 10,227(27.8) 5,379 (30.3) 24,950 (30.9) 
 55–64 1,109 (29.9) 10,439(28.3) 6,308 (35.5) 28,604 (35.4) 
 65–74 623 (16.8) 6,181 (16.8) 3,221 (18.1) 14,113 (18.1) 
 ≥75 240 (6.5) 2,581 (7.0) 754 (4.2) 3,115 (3.9) 
 
Median(IQR) age at diagnosis 
(years) 
56 (47-64) 55(47-64)  57 (50–64) 57 (50–64) 
Sex (%)     
 Males 2,520 (68.0) 25,074 (68.0) 11,687 (66.8) 52,633 (65.1) 
 Female 1,186 (32.0) 11,780 (32.0) 5,912 (33.3) 28,182 (34.9) 
Smoking status 
       Smoker 
       Ex-smoker 
       Never smoked 
       No available data 
 
1,673(45.1) 
647(17.5) 
791(21.3) 
595(16.1) 
    
   7,638(20.7) 
6,589(17.9) 
13,231(35.9) 
9,396(25.5) 
  
Disease stagea     
Compensated  1,859 (50.2) - 12,484 (70.2)  
Decompensated 1,847 (49.8) - 5,295 (29.8)  
Charlson comorbidity score (%)     
0 2,310 (62.3) 34,262 (92.7) 11,276 (63.4) 76,403 (94.5) 
1 793 (21.4) 1,358 (3.7) 3,043 (17.1) 2,347 (2.9) 
2 603 (16.3) 1,234 (3.4) 3,460 (19.5) 2,065 (2.6) 
     
Evidence of osteoporosis     
Diagnostic code +/- bisphosphonate 
prescription 
234(6.3) 1133(3.1) 547 (3.1) 1,366 (1.7) 
 
Previous densitometry scan 
 
 
3(0.01) 
 
      6(0.16) 
 
              16( 0.09)  
 
30(0.04) 
Other cirrhosis aetiologyb     
Autoimmune disease 30(0.8) - 44 (0.25) - 
Metabolic disease 157(4.2) - 303 (1.7) - 
Viral hepatitis 243(6.6) - 627 (3.5) - 
Only alcohol-related 3,290(88.8) - 16,824 (94.6) - 
     
            aBaveno classification   bpatients can have more than one other aetiology in addition to alcohol 
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Table 2:  Hip fracture rates and hazard ratios (HR) for alcoholic cirrhosis patients and population controls in the Danish and UK sample according to sub-
groups defined by age, gender, and decompensation status with 95% confidence intervals 
 
  English Cirrhosis patients Danish Cirrhosis patients 
  No. of 
hip 
fracture 
events 
Person 
years 
Rate per 1,000 
person years 
Adjusted HR1 
(95% CI)  
 
No. of hip 
fracture 
events 
Person-
years 
Rate per 1,000 
person years 
Adjusted HR1 (95% 
CI)    
Overall 108 9,483 11.4 [9.4 - 13.8] 5.5[4.3 - 6.9] 977 61,122 16.0[15.0, 17.0] 8.5[7.8–9.3] 
 
    Min-44  14 1,822 7.7 [4.6 - 12.9] 17.9 [7.8 - 40.8] 77 10,546 7.3 [5.8–9.1] 16.4 [11.4–23.6] 
    45–54 31 3,099 10.0 [7.0 - 14.2] 14.7[8.6 - 24.9] 297 21,712 13.7 [12.2–15.3] 13.1 [10.9–15.7] 
    55–64 33 2,958 11.2[7.9 - 15.7] 6.2[3.9 - 9.5] 363 20,360 17.8 [16.0–19.8] 9.8 [8.4–11.4] 
    65–74 19 1,226 15.5 [9.9 - 24.3] 3.2[1.9 - 5.4] 193 7361 26.2 [22.7–30.2] 5.9 [4.9–7.1] 
    75+ 11 378 29.1[16.1 - 52.6] 2.1[1.1 - 2.2] 47 1,143 41.1 [30.2–54.7] 3.0 [2.1–4.2] 
 
    Men 59 6,259 9.4 [7.3 - 12.2] 4.4[ 3.2 - 6.1] 571 38,638 14.8 [13.7–16.0] 9.0 [8.0–10.1] 
    Women 49 3,224 15.2 [11.5 - 20.1] 7.1[ 5.0 - 9.9] 406 22,484 18.1 [16.3–19.9] 7.9 [6.9–9.0] 
 
  Compensated 53 5,621 9.4 [7.2 -12.3] - 665 42,480 15.7 [14.5–16.9] - 
 Decompensated 55 3,862 14.2 [10.9 -18.5] - 312 18,642 16.7 [14.9–18.7] - 
Decompensated 
and/or HE2 
61 4,367 13.9[10.9-17.9] - 418 24,382 17.1 [15.5–18.9] - 
         
Evidence of 
osteoporosis 
26 837 31.0[21.1-45.6] - 44 1,245 35.3 [25.7–47.4] - 
             None 82 8,646 9.5[7.6-11.8] - 503 59,877 15.6 [14.6–16.6] - 
1 HR adjusted for age, sex and comorbidity for cirrhosis patients vs. population controls       
2 HE-Hepatic Encephalopathy, (includes alcoholic encephalopathy and Wernicke’s syndrome)  
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Table 3: Cirrhosis patients and population controls’ 5-year risk of a hip fracture by age group at inclusion, gender and compensation status with 95% 
confidence intervals (CI’s) 
 
 
 
                                      England Denmark 
 Cirrhosis patients Population controls Cirrhosis patients Population controls 
Overall  2.9[2.3-3.6] 0.8[0.7-0.9] 4.6 (4.3–5.0] 0.9 [0.8–0.9] 
Age 
group 
    
Min-44 2.2 [0.9 - 4.4] 0.2 [0.1 - 0.5] 2.5 [1.9–3.3] 0.1 [0.1–0.2] 
45–54 2.3 [1.4 - 3.4] 0.4 [0.3 - 0.6] 4.3 [3.8–4.9] 0.4 [0.3–0.5] 
55–64 2.7 [1.8 - 3.9] 0.7 [0.6 - 0.9] 5.0 [4.4–5.6] 0.7 [0.6–0.8] 
65–74 2.0 [1.1 - 3.2] 1.2 [1.1 - 3.1] 5.9 [5.1–6.8] 1.6 [1.4–1.6] 
75– 3.8 [1.9 - 6.7] 2.6 [2.1 - 3.1] 5.9 [4.3–8.0] 5.5 [4.7–6.5] 
Sex      
Male 2.4 [1.8 - 3.3] 0.8 [0.7 - 1.0] 4.2 [3.9–4.6] 0.7 [0.7–0.8] 
Female 4.3 [3.1 - 5.8] 1.2 [1.0 - 1.6] 5.5 [4.9–6.1] 1.1 [1.0–1.2] 
Disease severity     
Compensated  3.1 [2.3 - 4.1]       - 4.7 [4.3–5.1]           - 
Decompensated 3.1 [2.3 - 4.2]       - 4.6 [4.0–5.2]           - 
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Table 4: Alcoholic cirrhosis patients and population controls’ 30-day mortality risk (%) after a hip fracture with 95% confidence intervals (CI’s)       
 
 
 
 
 
 
 
 
  
 
 Alcholic cirrhosis patients                    Population controls    Age adjusted 
Mortality risk ratio 
(95% CI) 
 No. of deaths  No at risk Mortality risk No of deaths No. at risk Mortality risk   
English cohort          12   108 11.1[6.9-19.8]         19 377 5.0[ 3.4-8.2]     2.8 (1.9-3.9) 
Danish cohort           98   977 10.0 [8.3–12.1]         1,411 100 6.6 [5.5–8.0]     2.0 (1.5-2.7) 
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Figure 2: 5-year cumulative incidence for hip fractures by age group at inclusion. 
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Supplementary table 1: Details of selected prescriptions in English Cirrhosis cohort and control 
cohort. 
  
 Cirrhosis cohort 
N=3,706 
Control cohort 
N=36,854 
   
 Oral or injected 
steroids 
None 
<=Median (0.4) 
>Median 
                 
                 
 3,193(86.2) 
176(4.8) 
337(9.1) 
        
 
31,452(85.3) 
2,781(7.6) 
2,621(7.1) 
         Opiates  
None 
<=Median (0.9 ) 
>Median 
                    
2,142(57.8) 
   430(11.6) 
1,134(30.6) 
        
24,795(67.3) 
6,381(17.3) 
5,678(15.4) 
          Antidepressants 
None 
<=Median (0.8) 
>Median 
 
3,179 (85.8) 
  160(4.3) 
  367(9.9) 
 
32,751(88.9) 
2,154(5.8) 
1,949(5.3) 
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Supplementary table 2: Fracture rate and Hazard ratios with adjustment for drug exposure in English 
data. 
 
 
Model 1:  adjusted for age, sex and comorbidity 
Model 2: Model 1 + adjustment for exposure to opiates, steroids or antidepressants. 
 
  English Cirrhosis patients  
  No. of 
hip 
fracture 
events 
Person 
years 
Rate per 1,000 
person years 
Adjusted HR  
(95% CI)  
Model 1 
 
Adjusted HR 
(95% CI) 
Model 2 
Overall 108 9,483 11.4 [9.4 - 13.8] 5.5[4.3 - 6.9] 5.0[3.9-6.3] 
Age group(years)      
    Min-44  14 1,822 7.7 [4.6 - 12.9] 17.9 [7.8 - 40.8] 17.2[7.1-41.6] 
    45–54 31 3,099 10.0 [7.0 - 14.2] 14.7[8.6 - 24.9] 13.0[7.4-22.9] 
    55–64 33 2,958 11.2[7.9 - 15.7] 6.2[3.9 - 9.5] 5.9[3.8-9.2] 
    65–74 19 1,226 15.5 [9.9 - 24.3] 3.2[1.9 - 5.4] 2.9[1.7-5.0] 
    75+ 11 378 29.1[16.1 - 52.6] 2.1[1.1 - 2.2] 1.8[0.9-3.5] 
    Men 59 6,259 9.4 [7.3 - 12.2] 4.4[ 3.2 - 6.1] 4.3[3.1-5.9] 
    Women 49 3,224 15.2 [11.5 - 20.1] 7.1[ 5.0 - 9.9] 6.2[4.4-8.7] 
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(a) English data           (b) Danish data 
  
Supplementary figure 1: 5-year cumulative incidence for hip fractures comparing cirrhosis patients and controls with no major comorbidity (Charlson index 
score of 0. 
  
